About IVERIC bio
IVERIC bio is a Healthcare company based in New York (United States) founded in 2007, and was acquired by Astellas Pharma in April 2023. Gene therapy solutions for retinal diseases are developed. IVERIC bio has raised $206.77 million across 10 funding rounds from investors including Blackstone, Astellas Pharma and Novo Holdings. The company has 94 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
IVERIC bio was founded in 2007 in New York, United States, within the biotechnology sector. Focus is placed on gene therapies targeting retinal conditions. Operations involve advancing candidates such as Zimura, which addresses age-related macular degeneration, and IC-100, a mutation-independent therapy using an AAV5 vector. This approach reduces toxic rhodopsin from mutated genes while introducing healthy protein via a single delivery system.
- Headquarters New York, United States
- Employees 94
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website ivericbio.com
- Social LinkedIn
- Acquired by Astellas Pharma (Apr 2023)
- Total Equity Funding$206.77M (USD)
in 10 rounds
- Latest Funding Round$11.4M (USD), Private Equity Round
Oct 2018
- InvestorsBlackstone
& 3 more
- Employee Count94
- Acquired byAstellas Pharma
(Apr 2023)
Funding Insights of IVERIC bio
IVERIC bio has successfully raised a total of $206.77M across 10 strategic funding rounds. The most recent funding activity was a Private Equity Round of $11.4 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $206.77M
- Total Rounds 10
- Last Round Private Equity Round — $11.4M
- First Round $36M
(Aug 2007)
- Investors Count 3
All 10 funding rounds of IVERIC bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $11.4M | Private Equity Round | – | – | – |
| Jan 2014 | $41.7M | Private Equity Round | – | – | |
| Jun 2013 | $16.67M | Series C | – | – | – |
| May 2013 | $50M | Series C | – | – | |
| Jun 2012 | Series B | – | – | – | |
| Dec 2009 | $30M | Series B | – | – | |
| Dec 2009 | $15M | Series B | – | – | – |
| Oct 2009 | $3M | Seed | – | – | – |
| Oct 2009 | $3M | Series A | – | – | – |
| Aug 2007 | $36M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in IVERIC bio
IVERIC bio has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Astellas Pharma and Novo Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Venture capital fund focused on early-stage healthcare startups | svhealthinvestors.com | Boston, United States | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Generic pharmaceuticals are developed, manufactured, and marketed worldwide. | 1923 | astellas.com | Chiba, Japan |
Investor details for IVERIC bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IVERIC bio
45 people are tracked at IVERIC bio (13 in leadership, 1 in board & advisors, 31 in team); the tracked headcount is 94.
| Name | Role | Group |
|---|---|---|
Glenn Sblendorio | Leadership | |
Darah Biddle | Regional Business Director, Mid-atlantic | Leadership |
Karen Marchetti | Senior Director, Patient Marketing | Leadership |
Douglas Sottos | Sr Director Quality | Leadership |
Matthew Davis | Senior Director, Analytical Development And Quality Control | Leadership |
Paul Sandor | Executive Director, Quality Compliance | Leadership |
Don Luo | Senior Director, Biostatistics | Leadership |
Clara Song | Director, Medical Information, Promotional Review Committee, And Medical Review Committee | Leadership |
Ashish Patel | Vice President, Sales | Leadership |
Dina Joy Abulon | Medical Director, Clinical Lead | Leadership |
Carie Chandler | Region Business Director | Leadership |
Rocco Auletta | Executive Director, Controller | Leadership |
Sandra Weisgerber | Senior Director Of Financial Planning And Analysis | Leadership |
David R. Lally | Scientific Advisor | Board & advisors |
Jennifer Dindial | Territory Business Manager | Team |
Maureen Ahn | Territory Business Manager | Team |
Adena Hejl | Territory Business Manager | Team |
Morgan Miller | Territory Business Manager | Team |
Becky Voorhies | Territory Business Manager, Retina | Team |
Brett Oblon | Territory Business Manager | Team |
25 more people are available in the full profile.
Complete people profiles for IVERIC bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IVERIC bio
5 dated milestones of IVERIC bio across 16 years, from founding to its latest funding, stage changes and deals.
- Founded IVERIC bio is founded.
- Funding First funding round of $36.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Private Equity Round, of $11.4M.
- Exit Acquired by Astellas Pharma.
Competitors of IVERIC bio
IVERIC bio has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of IVERIC bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of IVERIC bio
The website of IVERIC bio (ivericbio.com) receives about 2.3K visits a month and ranks #5,186,881 among all websites worldwide, #5,922 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▼ 17.8% vs previous month
- Unique visitors1.3K
per month
- Global rank#5,186,881
among all websites
- Category rank#5,922
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit2.3
- Average visit1 min 42 sec
- DevicesDesktop 46% · Mobile 54%
Websites whose visitors overlap most with IVERIC bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
mmm-online.com | mmm-online.com | 100% | #392,799 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as IVERIC bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Iveric Bio
Complete news archive for IVERIC bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IVERIC bio
IVERIC bio was founded in 2007.
IVERIC bio is headquartered in New York, United States. It is registered at New York, New York, United States.
IVERIC bio is a funded company, having raised a total of $206.77M across 10 funding rounds to date. The company's 1st funding round was a Series A of $36M, raised on Aug 2007.
IVERIC bio has 94 employees.
IVERIC bio was founded in 2007 in New York, United States, within the biotechnology sector. Focus is placed on gene therapies targeting retinal conditions. Operations involve advancing candidates such as Zimura, which addresses age-related macular degeneration, and IC-100, a mutation-independent therapy using an AAV5 vector. This approach reduces toxic rhodopsin from mutated genes while introducing healthy protein via a single delivery system.
IVERIC bio's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
IVERIC bio has 4 investors. Key investors include Blackstone, Astellas Pharma, Novo Holdings, and SV Health Investors.
Yes. IVERIC bio was acquired by Astellas Pharma in April 2023.